Scilex in-licenses Datavault AI tech for biotech asset tokenization; $10M upfront, $2.55B milestones

Scilex Holding Co

Worldwide exclusive license from Datavault AI for tokenizing genomic, DNA, diagnostic, therapeutic data in biotech/pharma.
Non-refundable upfront fee $10M payable in four equal $2.5M quarterly installments starting Dec 31, 2025.
Potential sales milestone payments up to $2.55B and 5% royalty on net sales; minimum annual royalty $1M after 24 months.
Core patent includes 'Platform and Method for Tokenizing DNA Data' (U.S. Pat. App. 17/941,623) plus suite of issued/pending patents.
Scilex aims to create a Biotech Exchange platform for secure tokenization, trading, and monetization of biotech assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.